



an Open Access Journal by MDPI

Targeted Drug Delivery to Brain

Guest Editor:

Dr. Anjali Sharma

Department of Chemistry,
Washington State University,
Pullman, WA 99164-4630, USA

Deadline for manuscript
submissions:

closed (31 July 2023)

Message from the Guest Editor

The poor transport of therapeutics across various central nervous system barriers is a primary clinical challenge in the development of treatments for brain diseases. As a result, the majority of drugs for neurological diseases need to be administered at high doses, leading to systemic side effects and toxicities. Recent developments in the area of targeted brain-delivery strategies using nanotechnology, gene-therapy and cell-based therapeutics have shown significant promise for enhancing the efficacy and safety of drugs by specifically delivering them to targeted locations in the brain. This Special Issue of Biomedicines focuses on the recent advancements in the field of brain drug and gene-delivery strategies aiming for delivery to specific regions, cells, and sub-cellular locations within the brain for the treatment of unmet clinical needs in the area of neurological diseases. We invite original research and review articles focusing on the challenges associated with drug delivery across the brain and the development of nanoparticles or biologics-based brain-targeted platforms for drug-/gene-delivery, imaging, and diagnostic applications.



mdpi.com/si/99167

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)